

Anorganic bovine bone and a silicate-based synthetic bone activate different microRNAs

Palmieri Annalisa¹), Pezzetti Furio¹), Zollino Ilaria²), Avantaggiato Anna²), Scapoli Luca¹), Martinelli Marcella¹), Arlotti Marzia¹), Masiero Elena¹) and Francesco Carinci²)

¹)Department of Histology, Embryology and Applied Biology, University of Bologna and Center of Molecular Genetics, CARISBO Foundation, Bologna, Italy

²)Department of Medical-Surgical Sciences of Communication and Behaviour, Section of Maxillofacial Surgery, University of Ferrara, Ferrara, Italy

(Received 22 April and accepted 7 July 2008)

Abstract: Bio-Oss (BO), composed of anorganic bovine bone, is widely used in several bone regeneration procedures in oral surgery. PerioGlas (PG) is an alloplastic material that has been used for grafting of periodontal osseous defects since the 1990s. However, how these biomaterials alter osteoblast activity to promote bone formation is poorly understood. We attempted to address this question by using microRNA microarray techniques to investigate differences in translational regulation in osteoblasts exposed to BO and PG. By using miRNA microarrays containing 329 probes designed from human miRNA sequences, we investigated miRNAs whose expression was significantly modified in an osteoblast-like cell line (MG-63) cultured with BO vs PG. Three up-regulated miRNAs (mir-337, mir-200b, mir-377) and 4 down-regulated miRNAs (mir-130a, mir-214, mir-27a, mir-93) were identified. Our results indicated that BO and PG act on different miRNAs. Globally, PG causes activation of bone-forming signaling, whereas BO also activates cartilage-related pathways. (*J. Oral Sci.* 50, 301-307, 2008)

Keywords: bone graft; miRNA; microarray; gene expression; gene profiling.

Correspondence to Dr. Francesco Carinci, Department of Medical-Surgical Sciences of Communication and Behaviour, Section of Maxillofacial Surgery, University of Ferrara, Corso Giovecca, 203, 44100 Ferrara, Italy
Tel: +39-0532-455582
Fax: +39-0532-455582
E-mail: crc@unife.it

Introduction

Bio-Oss (BO) is a deproteinized sterilized bovine bone material comprising calcium-deficient carbonate apatite, and is chemically and physically identical to human bone (1-8). BO has a compressive strength of 35 Mpa and its porous nature (75-80% of the total volume) serves to greatly increase the surface area of the material, thus providing a substratum for increased angiogenesis and a scaffold for bone formation (1-8).

PerioGlas (PG) is an alloplastic material that has been used for grafting of periodontal osseous defects since the 1990s. In animal models it has been shown to facilitate good histological repair of surgically created defects. In monkey (9-11) PG demonstrates biocompatibility and osteoconductive activity. It is mostly resorbed and replaced by bone, and the remaining granules stay in close contact with bone. In a rabbit model, PG has been shown to be capable of improving bone healing at the interface between titanium dental implants and bone (12), whereas in ovariectomized rats it enhances de novo formation of bone trabeculae in extraction sockets (13).

In a clinical trial, bioactive glass was shown to be effective as an adjunct to conventional surgery in the treatment of intrabony defects (14) as well as dental extraction sites before implant placement, in order to implement bone regeneration and augment early fixation of the implant (15). However, PG has no regenerative properties for cementum and periodontal ligament (16).

Because the mechanism by which BO and PG stimulate osteoblast activity to promote bone formation is poorly

understood, we attempted to address this question by using microRNA microarray techniques.

MicroRNAs (miRNAs) represent a class of small, functional, noncoding RNAs of 19-23 nucleotides (nt) cleaved from 60- to 110-nt hairpin precursors (17,18). Hundreds of miRNAs have been identified in plants and animals, where they are involved in various biological processes, including cell proliferation and cell death during development, stress resistance, and fat metabolism, through the regulation of gene expression (19) via post-transcriptional RNA silencing pathways. The RNA interference (RNAi) and miRNA pathways regulate gene expression by inducing degradation and/or translational repression of target mRNAs. These pathways are generally initiated by various forms of double-stranded RNA (dsRNA), which are processed by Dicer, an RNase III family endonuclease, to 21-22-nt RNA molecules that serve as sequence-specific guides for silencing (20,21).

MicroRNAs are transcribed as long primary transcripts (pre-miRNAs), which are processed by a nuclear RNase III Drosha-containing complex into short hairpin intermediates (pre-miRNAs). Pre-miRNAs are transported to the cytoplasm, where they are further processed by a second RNase III-family enzyme called Dicer to generate 22-bp RNA duplexes with 2-nt 3' overhangs (22-25).

MicroRNAs are loaded onto an argonaute containing an effector ribonucleoprotein (RNP) complex, referred to as miRNP or RISC (RNA-induced silencing complex), which is capable of recognizing cognate mRNAs and inhibiting protein expression.

In the present study, we used a recently developed methodology for miRNA gene expression profiling based on the hybridization of a microchip, the Ncode Multi-Species miRNA Microarray (Invitrogen, Carlsbad, CA, USA), a slide printed with approximately 900 unique miRNA sequence probes for *Homo sapiens*, *Mus musculus*, *Rattus norvegicus*, *Drosophila melanogaster*, *Caenorhabditis elegans*, and *Danio rerio*. By analysis of the 329 human miRNAs sequences spotted on the array, we compared miRNA expression and consequently gene regulation in human MG63 cells treated with BO and PG.

Materials and Methods

Cell culture

Osteoblast-like cells (MG63) were cultured in sterile Falcon wells (Becton Dickinson, New Jersey, USA) containing Eagle's minimum essential medium (MEM) supplemented with 10% fetal calf serum (FCS) (Sigma, Chemical Co., St Louis, MO, USA) and antibiotics (penicillin 100 U/ml and streptomycin 100 µg/ml; Sigma Chemical Co.). Cultures were maintained in a 5% CO₂

humidified atmosphere at 37°C.

MG63 cells were collected and seeded at a density of 1×10⁵ cells/ml into 9-cm² (3-ml) wells by using 0.1% trypsin, 0.02% EDTA in Ca⁺⁺, Mg-free Eagle buffer for cell release. One set of wells was treated with Bio-Oss[®] (Geistlich, Wolhusen, Switzerland) at 10 mg/ml. Another set of wells was treated with PerioGlas[®] (US Biomaterials Corp., Alachua, FL) at 0.04 g/ml. After 24 h, when cultures were sub-confluent, the cells were processed for RNA extraction. This time point and doses were chosen in order to ensure that the results were comparable to previous studies performed by our group (26,27).

miRNA Microarray

MicroRNAs were extracted from the cells using a PureLink[™] miRNA Isolation Kit (Invitrogen, Milan, Italy). Four hundred nanograms of miRNA from each sample (treated and control) was used for hybridization of NCode[™] Multi-Species miRNA Microarray, a slide containing 329 Human miRNAs sequences in duplicate.

The Ncode[™] miRNA Labeling System (Invitrogen, Milan, Italy) was used for labeling and hybridization of miRNA to the microarray, in accordance with the manufacturer's instructions. Briefly, a poly(A) tail was added to each miRNA using a poly A polymerase and an optimized reaction buffer. Then a capture sequence was ligated to the miRNA using a bridging oligo(dT). Following a purification step, the tagged miRNAs were hybridized to the microarray and incubated overnight.

After incubation for 18-20 h, the array was washed and hybridized with Alexa Fluor[®] 3 (for PG) and Alexa Fluor[®] 5 (for BO) capture reagents in the first experiment, and then switched. After another wash the array was scanned using a standard microarray scanner (Axon Instruments, Sunnyvale, CA, USA).

After scanning, each spot was identified by means of a GAL (GenePixR Array List) file downloaded from www.invitrogen.com/ncode, that lists the identities and locations of all the probes printed on the array.

Images were quantified by GenePix 6.0 software (Axon Instruments, Sunnyvale, CA, USA). Signal intensities for each spot were calculated by subtracting local background from total intensities. The data were normalized using DNMD and Preprocessing (<http://gepas.bioinfo.cipf.es/cgi-bin/tools>) (28,29). This generates an average value of the two spot replicates of each miRNA.

To select the differentially expressed miRNA, the data obtained were analysed using the SAM (significance analysis of microarray) package (30).

For target predictions and validations, miRNAs were processed using miRBase Target, a web resource

(<http://microrna.sanger.ac.uk/targets/v4/>) developed by the Enright Lab at the Wellcome Trust Sanger Institute. This source uses an algorithm called miRanda to identify potential binding sites for a given miRNA in genomic sequences.

The gene target list was then processed by FatiGO (<http://fatigo.bioinfo.cnio.es>), a web interface that carries out simple data mining using Gene Ontology. The data mining involves assignment of the most characteristic Gene Ontology term to each cluster of regulated genes.

Results

Hybridization of miRNA to the sequences spotted on the slide allowed us to perform systematic analysis of microRNAs and to provide primary information on the regulation of translation processes induced by BO and PG. There were 3 up-regulated miRNAs (mir-337, mir-200b, mir-377) and 4 down-regulated miRNAs (mir-130a, mir-214, mir-27a, mir-93) for FDR (false discovery rate) = 0 and score > 4. Figure 1 shows the graphical output of SAM (Statistical Analysis for Microarray) for differentially expressed miRNAs. Because any given miRNA can potentially regulate thousands of genes, in this study we select only genes related to osteogenesis and bone remodeling (Table 1). Genes presenting conflicting regulation by miRNA were excluded.

We performed an indirect PCR validation rather than a direct one by comparing our results with those published previously by our group using the microarray technique (26,27). Lect1 was detected among the messenger RNAs up-regulated by down-regulated miRNAs, whereas CALCR was detected among the messenger RNAs down-regulated by up-regulated miRNAs, as reported previously (26,27).

Discussion

Previous histological studies have shown that most BO particles are surrounded by newly formed mature, compact bone with well-organized osteons (2,5,7,8). In some fields, osteoblasts are observed in the process of apposing bone directly on the particle surface. No gaps are present at the

bone-particle interface, and the bone is always in close contact with the particles (31-35). No inflammatory cell infiltrate has been observed around the particles or at the interface with bone.

PG is a silicate-based synthetic bone augmentation material that has been used to fill periodontal defects, showing bonding and integration to both soft tissue and bone. Previous studies using animal models have shown that PG facilitates good histological repair of surgically created defects (9-13). In clinical trials, PG has been effective as an adjunct to conventional surgery in the treatment of intrabony defects (14) as well as dental extraction sites (15).

As it is still unclear how these biomaterials alter osteoblast activity to promote bone formation, we attempted to address this question by using miRNA microarray to identify genes that are differentially translated in osteoblasts exposed to BO and PG.

MicroRNAs (miRNAs) are a recently discovered class of small, ~19-23-nucleotide non-coding RNA molecules. They are cleaved from 70-110-nucleotide hairpin precursors and play an important role in post-transcriptional regulation.




Fig. 1 SAM (significance analysis of microarray) plot of MG63 cells treated for 24 h with Bio-Oss® at a concentration of 100 mg/10 ml vs MG63 cells treated for 24 h with PerioGlas at a concentration of 0.04 g/ml.

Table 1 Down- and up- regulated genes

miRNA	Biological Function	Target Genes
Up-	skeletal development	CALCR, CASR, COL11A2, TNFRSF11B, PAPSS1, EBP, EN1, INBH, CMKLR1, COMP
	cartilage development	NOG
Down	skeletal development	MATN3, DLL3, CDH11, DLX5, PTH, IGF2, FGFR1, HOXA13, ADAMTS4
	cartilage development	LECT1, BMP1, MATN1
	bone remodeling	SPP1, AHSG, PMF1, ALPL

MicroRNAs are not translated into proteins: instead, they regulate the expression of other genes by either cleaving or repressing the translation of their messenger RNA (mRNA) targets.

Recent advances in spotted oligonucleotide microarray labeling and detection have enabled the use of this high-throughout technology for miRNA screening. Microarray is a molecular technology that enables parallel analysis of a very large number of DNA or RNA fragments, spanning a significant fraction of the human genome. Gene expression is facilitated by a process of (i) miRNA extraction, (ii) labeling (different dyes are used to stain reference untreated cells and investigated cells), (iii) and hybridization on slides containing miRNA probes. The slides are then scanned with a laser system, and two false color images are generated for each hybridization with miRNA from the investigated and the reference cells. The overall result is the generation of a so-called genetic portrait, corresponding to up- or down-regulated miRNAs in the cell system investigated.

Hybridization of miRNA derived from MG63 cells cultured with 100 mg/10 ml B vs those cultured with 0.04 g/ml PG to the sequences spotted on the slide allowed us to perform systematic analysis of miRNAs, and to obtain primary information about differences in translational regulation (Table 1).

Some genes up-regulated by BO (due to down-regulated miRNA) are homeoboxes, i.e. genes spatially and temporally regulated during embryonic development for control of morphogenesis. Noggin (NOG) inactivates members of the TGF-beta superfamily signaling proteins, such as BMP4. By diffusing through extracellular matrices more efficiently than members of the TGF-beta superfamily, noggin has a principal role in creating morphogenic gradients (36). The human engrailed homolog 1 (i.e. EN1) is implicated in the control of pattern formation during limb development (37). Other enhanced mRNAs encode extracellular matrix (ECM) components and enzymes such as COL1A2 and COMP (a non-collagenous ECM protein that binds to other ECM proteins such as collagen).

Hormonal receptors such as calcitonin receptor (CALCR) and calcium-sensing receptor (CASR) may also be up-regulated. CASR functions as a sensor for the parathyroid and kidney, determining the extracellular calcium concentration and thus helping to maintain a stable calcium concentration. Mutations that inactivate CASR cause familial hypocalciuric hypercalcemia, whereas mutations that activate CASR are the cause of autosomal dominant hypocalcemia (38). Osteoprotegerin (TNFRSF11B) is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a

negative regulator of bone resorption, binding specifically to its ligand, osteoprotegerin ligand (TNFSF11/OPGL), thus playing a key role in osteoclast development (39).

Some of the genes up-regulated by PG are homeoboxes, like DLX5 and HOXA13. DLX5 has a role in bone development and fracture healing. Mutation in this gene is associated with split-hand/split-foot malformation (40).

Another group of genes are hormones such as PTH and IGF2. IGF2 is member of the insulin family of polypeptide growth factors that are involved in development and growth (41). Additional proteins act in the extracellular matrix (ECM) compartment. BMP1 (or procollagen C proteinase) is a secreted metalloprotease that cleaves the C-terminal propeptides of procollagens I, II, and III and requires calcium for cartilage and bone formation (42). ALPL is a non-specific alkaline phosphatase that acts on matrix mineralization (43). MATN1 and 3 are enzymes involved in the formation of filamentous networks in the ECM of various tissues, playing a role in the development and homeostasis of cartilage and bone (44). Bone sialoprotein or osteopontin (SPP1) is a protein produced by osteoblasts upon stimulation with calcitriol and binds tightly to hydroxyapatite, thus anchoring osteoclasts to the mineral of bone matrix (45).

The genes discussed above represent only a limited number of those differentially regulated by the miRNAs listed in Table 1. We have briefly analyzed some of those whose functions are better known and directly related to bone formation, skeletal development, cartilage remodeling and bone production.

It should be noted that MG63 is a cell line and not normal osteoblasts. However, the use of a cell line allows higher data reproducibility, and avoids the variability of responses seen among individual patients. Primary cell cultures provide a source of normal cells, but they also contain contaminating cells of different types and cells in various states of differentiation. Moreover, we elected to perform the experiment after 24 h of culture in order to obtain information on the early genetic events that might occur in the early phase of grafting. In fact the postoperative period is of paramount importance for any successful grafting procedure.

In conclusion, BO and PG act on different miRNAs. Globally, PG causes activation of bone-forming signaling, whereas BO also activates cartilage-related pathways.

Acknowledgments

This work was supported by grants from University of Ferrara, Italy (F.C.), PRIN 2005 prot. 2005067555-002 (F.C.), Fondazione CARIFE (F.C.), and Fondazione CARISBO (F.P.).

References

- Berglundh T, Lindhe J (1997) Healing around implants placed in bone defects treated with Bio-Oss. An experimental study in the dog. *Clin Oral Implants Res* 8, 117-124
- Piattelli M, Favero GA, Scarano A, Orsini G, Piattelli A (1999) Bone reactions to anorganic bovine bone (Bio-Oss) used in sinus augmentation procedures: a histologic long-term report of 20 cases in humans. *Int J Oral Maxillofac Implants* 14, 835-840
- Valentini P, Abensur D (1997) Maxillary sinus floor elevation for implant placement with demineralized freeze-dried bone and bovine bone (Bio-Oss): a clinical study of 20 patients. *Int J Periodontics Restorative Dent* 17, 232-241
- Rodriguez A, Anastassov GE, Lee H, Buchbinder D, Wettan H (2003) Maxillary sinus augmentation with deproteinized bovine bone and platelet rich plasma with simultaneous insertion of endosseous implants. *J Oral Maxillofac Surg* 61, 157-163
- Tadjoedin ES, de Lange GL, Bronckers AL, Lyaruu DM, Burger EH (2003) Deproteinized cancellous bovine bone (Bio-Oss) as bone substitute for sinus floor elevation. A retrospective, histomorphometrical study of five cases. *J Clin Periodontol* 30, 261-270
- Merkx MA, Maltha JC, Stoelinga PJ (2003) Assessment of the value of anorganic bone additives in sinus floor augmentation: a review of clinical reports. *Int J Oral Maxillofac Surg* 32, 1-6
- Maiorana C, Sommariva L, Brivio P, Sigurta D, Santoro F (2003) Maxillary sinus augmentation with anorganic bovine bone (Bio-Oss) and autologous platelet-rich plasma: preliminary clinical and histologic evaluations. *Int J Periodontics Restorative Dent* 23, 227-235
- Hallman M, Cederlund A, Lindskog S, Lundgren S, Sennerby L (2001) A clinical histologic study of bovine hydroxyapatite in combination with autogenous bone and fibrin glue for maxillary sinus floor augmentation. Results after 6 to 8 months of healing. *Clin Oral Implants Res* 12, 135-143
- Fetner AE, Hartigan MS, Low SB (1994) Periodontal repair using PerioGlas in nonhuman primates: clinical and histologic observations. *Compendium* 15, 932, 935-938; quiz 939
- Karatzas S, Zavras A, Greenspan D, Amar S (1999) Histologic observations of periodontal wound healing after treatment with PerioGlas in nonhuman primates. *Int J Periodontics Restorative Dent* 19, 489-499
- Cancian DC, Hochuli-Vieira E, Marcantonio RA, Garcia Júnior IR (2004) Utilization of autogenous bone, bioactive glasses, and calcium phosphate cement in surgical mandibular bone defects in Cebus apella monkeys. *Int J Oral Maxillofac Implants* 19, 73-79
- Johnson MW, Sullivan SM, Rohrer M, Collier M (1997) Regeneration of peri-implant infrabony defects using PerioGlas: a pilot study in rabbits. *Int J Oral Maxillofac Implants* 12, 835-839
- Téofilo JM, Brentegani LG, Lamano-Carvalho TL (2004) Bone healing in osteoporotic female rats following intra-alveolar grafting of bioactive glass. *Arch Oral Biol* 49, 755-762
- Zamet JS, Darbar UR, Griffiths GS, Bulman JS, Brägger U, Bürgin W, Newman HN (1997) Particulate bioglass as a grafting material in the treatment of periodontal intrabony defects. *J Clin Periodontol* 24, 410-418
- Gatti AM, Simonetti LA, Monari E, Guidi S, Greenspan D (2006) Bone augmentation with bioactive glass in three cases of dental implant placement. *J Biomater Appl* 20, 325-339
- Nevins ML, Camelo M, Nevins M, King CJ, Oringer RJ, Schenk RK, Fiorellini JP (2000) Human histologic evaluation of bioactive ceramic in the treatment of periodontal osseous defects. *Int J Periodontics Restorative Dent* 20, 458-467
- Moss EG (2003) MicroRNAs in noncoding RNAs. In *Molecular biology and molecular medicine*, Barciszewski J, Erdmann VA eds, Landes Bioscience, Georgetown, 98-114
- Schmitter D, Filkowski J, Sewer A, Pillai RS, Oakeley EJ, Zavolan M, Svoboda P, Filipowicz W (2006) Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells. *Nucleic Acids Res* 34, 4801-4815
- Ambros V (2003) MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. *Cell* 113, 673-676
- Sontheimer EJ, Carthew RW (2005) Silence from within: endogenous siRNAs and miRNAs. *Cell* 122, 9-12
- Zamore PD, Haley B (2005) Ribo-gnome: the big world of small RNAs. *Science* 309, 1519-1524
- Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello CC (2001) Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control *C. elegans* developmental timing. *Cell* 106, 23-34
- Hutvágner G, McLachlan J, Pasquinelli AE, Bálint

- E, Tuschl T, Zamore PD (2001) A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. *Science* 293, 834-838
24. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH (2001) Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *C. elegans*. *Genes Dev* 15, 2654-2659
 25. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W (2004) Single processing center models for human Dicer and bacterial RNase III. *Cell* 118, 57-68
 26. Carinci F, Palmieri A, Martinelli M, Perrotti V, Piattelli A, Brunelli G, Arlotti M, Pezzetti F (2007) Genetic portrait of osteoblast-like cells cultured on PerioGlas. *J Oral Implantol* 33, 327-333
 27. Carinci F, Piattelli A, Degidi M, Palmieri A, Perrotti V, Scapoli L, Martinelli M, Laino G, Pezzetti F (2006) Genetic effects of anorganic bovine bone (Bio-Oss) on osteoblast-like MG63 cells. *Arch Oral Biol* 51, 154-163
 28. Vaquerizas JM, Dopazo J, Díaz-Urriarte R (2004) DNMAID: web-based diagnosis and normalization for microarray data. *Bioinformatics* 20, 3656-3658
 29. Herrero J, Díaz-Urriarte R, Dopazo J (2003) Gene expression data preprocessing. *Bioinformatics* 19, 655-656
 30. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 98, 5116-5121
 31. Haas R, Baron M, Donath K, Zechner W, Watzek G (2002) Porous hydroxyapatite for grafting the maxillary sinus: a comparative histomorphometric study in sheep. *Int J Oral Maxillofac Implants* 17, 337-346
 32. Artzi Z, Nemcovsky CE, Dayan D (2002) Bovine-HA spongiosa blocks and immediate implant placement in sinus augmentation procedures. Histopathological and histomorphometric observations on different histological stainings in 10 consecutive patients. *Clin Oral Implants Res* 13, 420-427
 33. Sennerby L, Lundgren S (1999) Histologic aspects of simultaneous implant and graft placement. In *The sinus bone graft*. Jensen OT ed, Quintessence, Chicago, 95-105
 34. Landi L, Pretel RW Jr, Hakimi NM, Setayesh R (2000) Maxillary sinus floor elevation using a combination of DFDBA and bovine-derived porous hydroxyapatite: a preliminary histologic and histomorphometric report. *Int J Periodontics Restorative Dent* 20, 574-583
 35. Froum SJ, Tarnow DP, Wallace SS, Rohrer MD, Cho SC (1998) Sinus floor elevation using anorganic bovine bone matrix (OsteoGraf/N) with and without autogenous bone: a clinical, histologic, radiographic, and histomorphometric analysis – Part 2 of an ongoing prospective study. *Int J Periodontics Restorative Dent* 18, 528-543
 36. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC (2003) Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). *J Bone Joint Surg Am* 85-A, 1544-1552
 37. Johnson RL, Tabin CJ (1997) Molecular models for vertebrate limb development. *Cell* 90, 979-990
 38. D'Souza-Li L, Canaff L, Janicic N, Cole DE, Hendy GN (2001) An acceptor splice site mutation in the calcium-sensing receptor (CASR) gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. *Hum Mutat* 18, 411-421
 39. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis *in vitro*. *Endocrinology* 139, 1329-1337
 40. Depew MJ, Lufkin T, Rubenstein JL (2002) Specification of jaw subdivisions by *Dlx* genes. *Science* 298, 381-385
 41. Constancia M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C, Reik W (2002) Placental-specific IGF-II is a major modulator of placental and fetal growth. *Nature* 417, 945-948
 42. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS (1996) Bone morphogenetic protein-1: the type I procollagen C-proteinase. *Science* 271, 360-362
 43. Goseki-Sone M, Orimo H, Iimura T, Miyazaki H, Oda K, Shibata H, Yanagishita M, Takagi Y, Watanabe H, Shimada T, Oida S (1998) Expression of the mutant (1735T-DEL) tissue-nonspecific alkaline phosphatase gene from hypophosphatasia patients. *J Bone Miner Res* 13, 1827-1834
 44. Chapman KL, Mortier GR, Chapman K, Loughlin J, Grant ME, Briggs MD (2001) Mutations in the

region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia. *Nat Genet* 28, 393-396

45. Reinholt FP, Hultenby K, Oldberg A, Heinegard D (1990) Osteopontin – a possible anchor of osteoclasts to bone. *Proc Natl Acad Sci U S A* 87, 4473-4475